Bristol-Myers Squibb (BMY) won the dismissal of a proposed class-action lawsuit in a federal court accusing it of using anticompetitive tactics to maintain monopoly on its blood cancer drug Pomalyst, multiple media outlets reported Wednesday.
US District Judge Edgardo Ramos in New York City said in a 70-page decision that Blue Cross Blue Shield of Louisiana and other Pomalyst purchasers failed to show that the company violated the federal Sherman act, Reuters reported.
Filed in September 2023, the suit claimed the drug to have been subject to generic competition by October 2020 and Bristol-Myers' tactics caused these companies to overpay by hundreds of millions, Fierce Pharma reported.
The lawsuit accused Bristol-Myers of obtaining illegal patents to the drug and then in order to maintain a monopoly filing sham lawsuits against generic drugmakers.
Price: 53.12, Change: +0.05, Percent Change: +0.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.